Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma

Hisakazu Nishimori; Nobuharu Fujii; Yoshinobu Maeda; Ken Ichi Matsuoka; Katsuto Takenaka; Katsuji Shinagawa; Kazuma Ikeda; Keitaro Matsuo; Mine Harada; Mitsune Tanimoto

Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma

Hisakazu Nishimori, Nobuharu Fujii, Yoshinobu Maeda, Ken Ichi Matsuoka, Katsuto Takenaka, Katsuji Shinagawa, Kazuma Ikeda, Keitaro Matsuo, Mine Harada, Mitsune Tanimoto

Center for Cellular and Molecular Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. Patients and Methods: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. Results: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34⁺ cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months. Conclusion: IDEA is an effective secondline chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.

Original language	English
Pages (from-to)	1749-1754
Number of pages	6
Journal	Anticancer research
Volume	29
Issue number	5
Publication status	Published - May 2009

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a3da8a872be54b15b38fcc41b5ea4631,

title = "Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma",

abstract = "Background: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. Patients and Methods: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. Results: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34+ cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months. Conclusion: IDEA is an effective secondline chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.",

author = "Hisakazu Nishimori and Nobuharu Fujii and Yoshinobu Maeda and Matsuoka, {Ken Ichi} and Katsuto Takenaka and Katsuji Shinagawa and Kazuma Ikeda and Keitaro Matsuo and Mine Harada and Mitsune Tanimoto",

year = "2009",

month = may,

language = "English",

volume = "29",

pages = "1749--1754",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma

AU - Nishimori, Hisakazu

AU - Fujii, Nobuharu

AU - Maeda, Yoshinobu

AU - Matsuoka, Ken Ichi

AU - Takenaka, Katsuto

AU - Shinagawa, Katsuji

AU - Ikeda, Kazuma

AU - Matsuo, Keitaro

AU - Harada, Mine

AU - Tanimoto, Mitsune

PY - 2009/5

Y1 - 2009/5

N2 - Background: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. Patients and Methods: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. Results: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34+ cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months. Conclusion: IDEA is an effective secondline chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.

AB - Background: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. Patients and Methods: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. Results: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34+ cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months. Conclusion: IDEA is an effective secondline chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.

UR - http://www.scopus.com/inward/record.url?scp=67650095258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650095258&partnerID=8YFLogxK

M3 - Article

C2 - 19443398

AN - SCOPUS:67650095258

SN - 0250-7005

VL - 29

SP - 1749

EP - 1754

JO - Anticancer Research

JF - Anticancer Research

IS - 5

ER -

Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this